{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T01:32:43Z","timestamp":1773365563764,"version":"3.50.1"},"reference-count":39,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,8,1]]},"abstract":"<jats:p>Objective. Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator that has become part of the standard management for persistent pulmonary hypertension of the newborn (PPHN). This treatment modality, like many in neonatology, has not been well studied using quantitative economic techniques. The objective of this study was to evaluate the economic impact of adding iNO to the treatment protocol of PPHN for term infants from birth to the time of discharge from their initial hospitalization.<\/jats:p><jats:p>Methods. We used decision analysis modeling from a societal perspective to obtain an incremental cost-effectiveness ratio. Outcome probabilities were taken from the medical literature and a cohort of 123 infants who were treated with PPHN at The Children\u2019s Hospital of Philadelphia between 1991 and 2002. Costs were estimated from daily resources used by these infants in 2001 dollars. Survival and quality-adjusted life years were used as effectiveness measures. One-way, threshold, and probabilistic sensitivity analyses were performed to assess the robustness of the base-case estimate.<\/jats:p><jats:p>Results. The addition of iNO to the treatment regimen of PPHN increased the cost of treating an infant by an average of $1141, primarily from an increased number of mechanical ventilation days. Use of iNO led to 3.4% more lives saved and a 6% increase in the average utility gained per infant. The incremental cost-effectiveness ratio was $33\u00a0234 per life saved and $19\u00a0022 per quality-adjusted life year gained. The model was robust to changes in outcome probabilities, cost, and utility variables. Only 3.6% of the trials using probabilistic sensitivity analysis found iNO to be more expensive with a worse outcome than conventional therapy alone, whereas 35.7% of the trials found iNO to be cheaper and more effective than conventional treatment alone.<\/jats:p><jats:p>Conclusions. iNO is cost-effective but not cost-saving in treating infants with PPHN from a societal perspective. There are critical time points during an infant\u2019s hospitalization that could improve the efficiency and consequently the cost of care for this patient population.<\/jats:p>","DOI":"10.1542\/peds.114.2.417","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:53:04Z","timestamp":1092444784000},"page":"417-426","source":"Crossref","is-referenced-by-count":23,"title":["Cost-Effectiveness of Inhaled Nitric Oxide for the Management of Persistent Pulmonary Hypertension of the Newborn"],"prefix":"10.1542","volume":"114","author":[{"given":"Scott A.","family":"Lorch","sequence":"first","affiliation":[{"name":"Department of Pediatrics"},{"name":"Division of Neonatology and Center for Outcomes Research, Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania"},{"name":"Center for Clinical Epidemiology and Biostatistics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avital","family":"Cnaan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Barnhart","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology and Biostatistics"},{"name":"Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2004,8,1]]},"reference":[{"key":"2021121006432817800_R1","doi-asserted-by":"crossref","unstructured":"Lewit EM, Baker LS, Corman H, Shiono PH. The direct cost of low birth weight. Future Child.1995;5:35\u201356","DOI":"10.2307\/1602506"},{"key":"2021121006432817800_R2","doi-asserted-by":"crossref","unstructured":"Boyle MH, Torrance GW, Sinclair JC, Horwood SP. Economic evaluation of neonatal intensive care of very-low-birth-weight infants. N Engl J Med.1983;308:1330\u20131337","DOI":"10.1056\/NEJM198306023082206"},{"key":"2021121006432817800_R3","doi-asserted-by":"crossref","unstructured":"Mauskopf JA, Backhouse ME, Jones D, et al. Synthetic surfactant for rescue treatment of respiratory distress syndrome in premature infants weighing from 700 to 1350 grams: impact on hospital resource use and charges. J Pediatr.1995;126:94\u2013101","DOI":"10.1016\/S0022-3476(95)70509-0"},{"key":"2021121006432817800_R4","doi-asserted-by":"crossref","unstructured":"Phibbs CS, Phibbs RH, Wakeley A, Schlueter MA, Sniderman S, Tooley WH. Cost effects of surfactant therapy for neonatal respiratory distress syndrome. J Pediatr.1993;123:953\u2013962","DOI":"10.1016\/S0022-3476(05)80394-4"},{"key":"2021121006432817800_R5","doi-asserted-by":"crossref","unstructured":"Ohls RK, Osborne KA, Christensen RD. Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo-controlled trial. J Pediatr.1995;126:421\u2013426","DOI":"10.1016\/S0022-3476(95)70462-0"},{"key":"2021121006432817800_R6","doi-asserted-by":"crossref","unstructured":"Roberts TE. Economic evaluation and randomized controlled trial of extracorporeal membrane oxygenation: UK collaborative trial. The Extracorporeal Membrane Oxygenation Economics Working Group. BMJ.1998;317:911\u2013915","DOI":"10.1136\/bmj.317.7163.911"},{"key":"2021121006432817800_R7","doi-asserted-by":"crossref","unstructured":"Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics.1999;104:419\u2013427","DOI":"10.1542\/peds.104.3.419"},{"key":"2021121006432817800_R8","doi-asserted-by":"crossref","unstructured":"Halpern MT, Read JS, Ganoczy DA, Harris DR. Cost-effectiveness of cesarean section delivery to prevent mother-to-child transmission of HIV-1. AIDS.\u20082000;14:691\u2013700","DOI":"10.1097\/00002030-200004140-00008"},{"key":"2021121006432817800_R9","doi-asserted-by":"crossref","unstructured":"Mrus JM, Yi MS, Eckman MH, Tsevat J. The impact of expected HIV transmission rates on the effectiveness and cost of ruling out HIV infection in infants. Med Decis Making.2002;22(suppl):S38\u2013S44","DOI":"10.1177\/027298902237710"},{"key":"2021121006432817800_R10","doi-asserted-by":"crossref","unstructured":"Lee SK, Normand C, McMillan D, Ohlasson A, Vincer M, Lyons C. Evidence for changing guidelines for routine screening for retinopathy of prematurity. Arch Pediatr Adolesc Med.2001;155:387\u2013395","DOI":"10.1001\/archpedi.155.3.387"},{"key":"2021121006432817800_R11","doi-asserted-by":"crossref","unstructured":"Zupancic JA, Richardson DK, Lee K, McCormick MC. Economics of prematurity in the era of managed care. Clin Perinatol.2000;27:483\u2013497","DOI":"10.1016\/S0095-5108(05)70032-4"},{"key":"2021121006432817800_R12","doi-asserted-by":"crossref","unstructured":"Christou H, Van Marter LJ, Wessel DL, et al. Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn. Crit Care Med.2000;28:3722\u20133727","DOI":"10.1097\/00003246-200011000-00031"},{"key":"2021121006432817800_R13","doi-asserted-by":"crossref","unstructured":"Clark RH, Kueser TJ, Walker MW, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med.2000;342:469\u2013474","DOI":"10.1056\/NEJM200002173420704"},{"key":"2021121006432817800_R14","doi-asserted-by":"crossref","unstructured":"Davidson D, Barefield ES, Kattwinkel J, et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO\/PPHN Study Group. Pediatrics.1998;101:325\u2013334","DOI":"10.1542\/peds.101.3.325"},{"key":"2021121006432817800_R15","doi-asserted-by":"crossref","unstructured":"The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med.1997;336:597\u2013604","DOI":"10.1056\/NEJM199702273360901"},{"key":"2021121006432817800_R16","doi-asserted-by":"crossref","unstructured":"Roberts JD Jr, Fineman JR, Morin FC III, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. N Engl J Med.1997;336:605\u2013610","DOI":"10.1056\/NEJM199702273360902"},{"key":"2021121006432817800_R17","doi-asserted-by":"crossref","unstructured":"Wessel DL, Adatia I, Van Marter LJ, et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics.1997;100(5). Available at: pediatrics.org\/cgi\/content\/full\/100\/5\/e7","DOI":"10.1542\/peds.100.5.e7"},{"key":"2021121006432817800_R18","doi-asserted-by":"crossref","unstructured":"Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev.2001(4):CD000399","DOI":"10.1002\/14651858.CD000399"},{"key":"2021121006432817800_R19","doi-asserted-by":"crossref","unstructured":"Jacobs P, Finer NN, Robertson CM, Etches P, Hall EM, Saunders LD. A cost-effectiveness analysis of the application of nitric oxide versus oxygen gas for near-term newborns with respiratory failure: results from a Canadian randomized clinical trial. Crit Care Med.2000;28:872\u2013878","DOI":"10.1097\/00003246-200003000-00043"},{"key":"2021121006432817800_R20","doi-asserted-by":"crossref","unstructured":"Jacobs P, Finer NN, Fassbender K, Hall E, Robertson CMT. Cost-effectiveness of inhaled nitric oxide in near-term and term infants with respiratory failure: eighteen to 24-month follow-up for Canadian patients. Crit Care Med.2002;30:2330\u20132334","DOI":"10.1097\/00003246-200210000-00023"},{"key":"2021121006432817800_R21","doi-asserted-by":"crossref","unstructured":"Drummond MF, Davies L. Economic analysis alongside clinical trials: revisiting the methodological issues. Int J Technol Assess Health Care.1991;7:561\u2013573","DOI":"10.1017\/S0266462300007121"},{"key":"2021121006432817800_R22","doi-asserted-by":"crossref","unstructured":"Cutler DM, Huckman RS. Technological development and medical productivity: the diffusion of angioplasty in New York state. J Health Econ.2002;22:187\u2013217","DOI":"10.1016\/S0167-6296(02)00125-X"},{"key":"2021121006432817800_R23","doi-asserted-by":"crossref","unstructured":"Cutler D, McClellan M. Is technological change in medicine worth it? Health Aff.\u20082001;20:11\u201329","DOI":"10.1377\/hlthaff.20.5.11"},{"key":"2021121006432817800_R24","doi-asserted-by":"crossref","unstructured":"Detsky AS, Naglie G, Krahn MD, Redelmeier DA, Naimark D. Primer on medical decision analysis: part 2\u2014building a tree. Med Decis Making.1997;17:126\u2013135","DOI":"10.1177\/0272989X9701700202"},{"key":"2021121006432817800_R25","doi-asserted-by":"crossref","unstructured":"Dolan P. Modeling valuations for EuroQOL health states. Med Care.1997;35:1095\u20131108","DOI":"10.1097\/00005650-199711000-00002"},{"key":"2021121006432817800_R26","doi-asserted-by":"crossref","unstructured":"Rogowski J. Measuring the cost of neonatal and perinatal care. Pediatrics.1999;103:329\u2013335","DOI":"10.1542\/peds.103.SE1.329"},{"key":"2021121006432817800_R27","unstructured":"Kotagal UR, Perlstein PH, Atherton HD, Donovan EF. The influence of day of life in predicting the inpatient costs for providing care to very low birth weight infants. Am J Manag Care.1997;3:217\u2013225"},{"key":"2021121006432817800_R28","doi-asserted-by":"crossref","unstructured":"Chalom R, Raphaely RC, Costarino AT Jr. Hospital costs of pediatric intensive care. Crit Care Med.1999;27:2079\u20132085","DOI":"10.1097\/00003246-199910000-00001"},{"key":"2021121006432817800_R29","unstructured":"Bureau of Labor Statistics. National Compensation Survey\u2014Wages. Washington, DC: Government Printing Office; 2002"},{"key":"2021121006432817800_R30","unstructured":"Centers for Medicare and Medicaid Services. National physician fee schedule relative value file. Washington, DC: Government Printing Office; 2002"},{"key":"2021121006432817800_R31","unstructured":"Centers for Medicare and Medicaid Services. Clinical diagnostic laboratory fee schedule. Washington, DC: Government Printing Office; 2002"},{"key":"2021121006432817800_R32","unstructured":"Drug Topics Red Book. Montvale, NJ: Medical Economics Company; 2001"},{"key":"2021121006432817800_R33","unstructured":"Bureau of Labor Statistics. Consumer Price Index. Washington, DC: Government Printing Office; 2002"},{"key":"2021121006432817800_R34","doi-asserted-by":"crossref","unstructured":"Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making.1998;18(suppl):S68\u2013S80","DOI":"10.1177\/0272989X98018002S09"},{"key":"2021121006432817800_R35","doi-asserted-by":"crossref","unstructured":"Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996","DOI":"10.1093\/oso\/9780195108248.001.0001"},{"key":"2021121006432817800_R36","doi-asserted-by":"crossref","unstructured":"Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. Med Decis Making.1985;5:157\u2013177","DOI":"10.1177\/0272989X8500500205"},{"key":"2021121006432817800_R37","doi-asserted-by":"crossref","unstructured":"Critchfield GC, Willard KE. Probabilistic analysis of decision trees using Monte Carlo simulation. Med Decis Making.1986;6:85\u201392","DOI":"10.1177\/0272989X8600600205"},{"key":"2021121006432817800_R38","doi-asserted-by":"crossref","unstructured":"Halpern EF, Weinstein MC, Hunink MGM, Gazelle GS. Representing both first- and second-order uncertainties by Monte Carlo simulation for groups of patients. Med Decis Making.2000;20:314\u2013322","DOI":"10.1177\/0272989X0002000308"},{"key":"2021121006432817800_R39","doi-asserted-by":"crossref","unstructured":"St. John EB, Nelson KG, Cliver SP, Bishnoi RR, Goldenberg RL. Cost of neonatal care according to gestational age at birth and survival status. Am J Obstet Gynecol.2000;182:170\u2013175","DOI":"10.1016\/S0002-9378(00)70509-6"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/114\/2\/417\/1017162\/zpe00804000417.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/114\/2\/417\/1017162\/zpe00804000417.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T05:11:54Z","timestamp":1705209114000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/114\/2\/417\/64612\/Cost-Effectiveness-of-Inhaled-Nitric-Oxide-for-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,1]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2004,8,1]]},"published-print":{"date-parts":[[2004,8,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.114.2.417","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8,1]]}}}